SEARCH

SEARCH BY CITATION

Keywords:

  • Doppler ultrasound;
  • placental insufficiency;
  • placental pathology;
  • placental ultrasound;
  • randomized control trial;
  • unfractioned heparin

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

Summary. Objective: To conduct a pilot randomized controlled trial of unfractionated heparin (UFH) in women considered at high risk of placental insufficiency in the second trimester. Methods: Women with either false-positive first trimester (pregnancy-associated placental protein-A [PAPP-A] < 0.35 MoM) or second trimester (alpha-fetoprotein [AFP] > 2.0 MoM, inhibin > 3.0 MoM, human chorionic gonadotropin > 4.0 MoM) serum screening tests or medical/obstetric risk factors were screened for placental insufficiency by sonographic evaluation of the placenta and uterine artery Doppler between 18 and 22 weeks. Thrombophilia screen-negative women with two or three abnormal test categories were randomized by 23+6 weeks to self-administration of subcutaneous unfractionated heparin (UFH) 7500 IU twice daily until birth or 34 weeks, or to standard care. Maternal anxiety and other maternal-infant outcomes were determined. Results: Thirty-two out of 41 eligible women consented, with 16 women randomized to UFH and 16 to standard care. There was no statistically significant difference identified between the two treatment groups (standard care vs. UFH) for the following: maternal anxiety score (mean [standard deviation]), 14.2 [± 1.6] vs. 14.0 [± 1.8]; birth weight (median [range]), 1795 [470–3295]g vs. 1860 [730–3050]g; perinatal death, 3 vs. 0; severe preeclampsia, 2 vs. 6; placental weight < 10th percentile, 7 vs. 4; or placental infarction, 4 vs. 3. Conclusion: Our study design identified women at high risk of adverse maternal-infant outcomes attributable to placental insufficiency. Women with evidence of placental insufficiency were willing to undergo randomization and self-administration of UFH without increased maternal anxiety.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

Prophylactic anticoagulation during pregnancy, with the aim of preventing adverse maternal-infant outcomes associated with placental insufficiency, is an attractive concept proposed over 35 years ago [1]. It is based on the observation that the extent of placental infarction correlates with the severity of preeclampsia and intrauterine growth restriction (IUGR) [1], and the assumption that heparin effectively prevents placental infarction [2]. We recently performed a systematic review of the literature [3] that identified four randomized controlled trials, involving 324 women, where heparin (alone or in combination with dipyridamole) was compared with no treatment [4–7]. Collectively these studies found no significant differences in perinatal mortality or preterm birth < 34 weeks’ gestation, though heparin significantly reduced the risk of preeclampsia and birth weight < 10th percentile [3].

The original hypothesis that heparin promotes improved pregnancy outcomes via its anticoagulant properties within the spiral arteries and the intervillous space has never been adequately tested because, to date, no trial has included placental pathology. Among women with confirmed placental infarction, the rates of severe preeclampsia and IUGR are high, yet only a subset have a detectable thrombophilia disorder [8]. Despite common minor side effects such as painful bruising and the rare but serious complication of vertebral collapse from osteopenia, thrombophilic women with previous pregnancy complications are increasingly prescribed prophylactic subcutaneous doses of either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in subsequent pregnancies [9]. This practise lacks evidence and is the subject of an ongoing clinical trial (http://clinicaltrials.gov/ct2/show/NCT00967382). Preliminary evidence that heparin may exert beneficial effects in women with a negative thrombophilia screen [5] or promote improved implantation with in-vitro fertilization [10] underscores the importance of defining the potential benefits and risks of heparin in women considered at risk of placental insufficiency from adequately-powered randomized controlled trials.

Placental infarction is rare in otherwise normal pregnancies. In a recent single-centre retrospective cohort of 180 singleton pregnancies with placental infarction, the majority of placentas were small and exhibited histologic abnormalities in both the utero-placental vascular bed and in the development of the placental villi [8]. These observations suggest that normal placental development confers intrinsic anticoagulant properties, via both hemostasis regulation at the surface of the villi and the attainment of a high utero-placental blood flow velocity within the placenta due to erosion of the distal segments of the spiral arterioles by the invasive extravillous trophoblast cells [11]. The ability to non-invasively demonstrate several elements of placental function in the first half of pregnancy, in order to define the subsequent risk of adverse perinatal outcomes due to thrombotic vascular disease of the placenta, forms the rationale for restricting the evaluation of the role of heparin to a subset of so-called high-risk pregnant women with multiply-abnormal test results [12]. These tests are presently available during standard antenatal care and comprise three categories: first, re-interpretation of the maternal serum screening tests for spina bifida and Down’s syndrome [13]; second, uterine artery Doppler at 19–22 weeks [14]; and third, placental morphology (size, shape and internal texture) [15]. Used alone, these tests do not achieve sufficient test characteristics to merit introduction as a screening program for adverse perinatal outcomes [14], yet when combined, can identify a subset of women with over 40% positive predictive values for serious adverse maternal and/or perinatal outcomes [12,15]. Therefore in our experience, over 60% of so-called high-risk women considered at risk of placental insufficiency based solely on clinical risk factors have normal tests of placental function that over-ride their background risks, to result in near-term favourable outcomes [12]. We therefore adopted the rationale of placental function testing in order to restrict the definition of ‘high-risk women’ to a subset of women with multi-parameter evidence of placental dysfunction in the second trimester. The aims of our pilot randomized trial were to assess the feasibility of this recruitment strategy and to monitor its impact upon psychological health.

Methods

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

Following Mount Sinai Hospital Research Ethics Board approval (MSHREB# 06-0246-A) we conducted a pilot randomized controlled trial at Mount Sinai Hospital, Toronto, Canada, between March 2007 and May 2010. Eligible women (n = 41) were approached in the high-risk Placenta Clinic, with 32 women providing written informed consent to participate. All women had prior pregnancy dating by ultrasound between 8 and 13 weeks’ gestation using crown rump length measurements.

Inclusion criteria

Women were eligible for the study if they had a singleton pregnancy between 18+0 and 23+6 weeks’ gestation, a negative maternal thrombophilia screen and evidence of placental dysfunction in the current pregnancy, determined by two or three of the following test categories: (i) abnormal biochemical markers on first trimester, second trimester or integrated maternal serum screening tests for trisomy 21 and neural tube defects; (ii) sonographic evidence of abnormal placental morphology; and (iii) abnormal uterine artery Doppler waveforms. In a previous cohort study of 212 clinically high-risk women, these tests were shown to have a positive predictive value of 74% for IUGR with delivery <34 weeks' gestation, and 45% for any delivery <34 weeks' gestation [12].

Placental biochemistry  Placental biochemistry  was assessed by reinterpretation of first and second trimester maternal serum screening values reported as multiples of the median (MoM) [13]. Abnormal placental biochemistry was defined as one or more of: pregnancy-associated protein-A (PAPP-A) < 0.35 MoM, alpha fetoprotein (AFP) > 2.0 MoM, inhibin > 3.0 MoM or total human chorionic gonadotrophin (hCG) > 4.0 MoM.

Placental morphology  Placental morphology  was assessed by real-time ultrasound imaging using previously developed criteria [12,16]. Anterior and posterior placentas were measured using a single set of callipers while fundal placentas were measured using two sets of callipers (edges to mid-portion of the central placental thickness). Abnormal placental morphology was defined as one or more of the following: (i) abnormal shape, as either the central placental thickness > 4 cm, or the central placental thickness > 50% of maximum length; (ii) abnormal length, as maximum placental length < 10 cm; (iii) abnormal texture, as either the presence of one or more echogenic cystic lesions (ECL) [17], or a ‘jelly-like’ appearance with turbulent uteroplacental flow visible due to lack of normal villous development [18].

Uterine artery Doppler  Uterine artery Doppler was performed on the proximal uterine arteries, which were located at their cross-over point with the external iliac artery using color flow mapping to obtain waveforms by pulsed Doppler [19]. Abnormal uterine artery Doppler was defined as a mean pulsatility index (PI) value > 1.45 with bilateral early diastolic notches.

Exclusion criteria

Women with a positive thrombophilia screen (defined as heterozygous or homozygous for the prothrombin 20210G>A or the factor V Leiden R506Q mutations, or a positive test for either lupus anticoagulant or IgG cardiolipin antibody > 15 GPL), thrombocytopenia (platelet count < 150 × 10−9 L−1), any requirement for antepartum heparin therapy, or vaginal bleeding, or women with a pregnancy complicated by known or suspected fetal structural or chromosomal abnormality, subchorionic hematoma on ultrasound or severe early-onset intrauterine growth restriction (IUGR) prior to trial entry, were excluded. Severe early-onset IUGR was defined as umbilical artery Doppler pulsatility index > 90th centile for gestation in a free loop of umbilical cord, with fetal biometry measurements (two of biparietal diameter [BPD], head circumference [HC], abdominal circumference [AC] and femur length [FL]) > 2 weeks smaller than predicted by gestational age.

Eligible women who provided written informed consent were randomized using a central telephone randomization service. During the automated telephone call, women were allocated a study identification number and their allocated treatment group was stated (either heparin group or standard care group). Women and their caregivers were not blinded to treatment allocation. The randomization was computer generated, used balanced variable blocks, and was prepared by a statistician not involved with recruitment or clinical care.

UFH group  Women randomized to the heparin group received specific written instructions and instructions from a trial nurse (supervised by a hematologist (AM)) in the self-administration of subcutaneous unfractionated heparin (UFH). They injected 7500 IU, given as 0.3 cc of UFH subcutaneously (heparin sodium injection, 25 000 IU mL−1, LEO*S.C.) using an insulin syringe (BD Ultra-fine II Insulin Syringe; BD Consumer Healthcare, Oakville, Canada 1 cc, 8 mm, 30 gauge) twice a day from randomization until 34 completed weeks of gestation or delivery (whichever occurred first). They were instructed to inject into the lower abdomen or lateral thighs on a rotating basis. The drug and syringes were paid for by the grant.

Standard care group  Women randomized to the standard care group received ongoing antenatal surveillance provided through the antenatal clinic, but were not administered medication.

Low-dose aspirin was not subsequently taken by women in the heparin group. Eight women in the standard care group took aspirin until 34 completed weeks of gestation or delivery (whichever occurred first).

Ascertainment of outcomes

All women were followed with clinic visits that included obstetric ultrasound examinations, either as full care and delivery at Mount Sinai Hospital (n = 31) or shared care with delivery at the referral community hospital (n = 1). Weight, blood pressure and urinalysis were recorded at each visit and any patient with +1 dipstick or more on urinalysis had a midstream urine culture and a urine protein/creatinine ratio test. A maternal complete blood count (CBC) was checked 1 week after starting UFH, every 2 weeks thereafter and at 26 weeks in both arms at the time of the 50 g glucose challenge test. UFH was discontinued if the platelet count was < 100 × 10−9 L−1. Ultrasound examinations for fetal growth (HC, BPD, AC and FL) were performed as a minimum every 4 weeks, including the amniotic fluid index, umbilical artery Doppler PI, and biophysical profile. If the estimated fetal weight was < 10th percentile, ultrasound examinations were increased to a minimum of weekly and incorporated Doppler studies of the fetal middle cerebral artery and ductus venosus. Serial ultrasound examinations also included imaging of the placenta and uterine artery Doppler, but were not used for clinical management. Women found to have new onset hypertension (blood pressure ≥ 140/90 mmHg) were either evaluated in our day unit or admitted to hospital. UFH was discontinued following the diagnosis of severe preeclampsia due to the associated risk of thrombocytopenia, but was otherwise continued until 34 weeks of gestation or delivery (whichever occurred first). Three maternal-fetal medicine specialists (JCPK, RW and JK) managed all 32 patients in a uniform manner.

At the time of enrollment in the study, women were asked to complete a short questionnaire related to their emotional health and wellbeing using the MOS 36-item short form health survey [20], the Spielberger State-Trait Inventory Self Evaluation Questionnaire [21] and the Edinburgh Postnatal Depression Score (EPDS) [22]. At each prenatal visit, women were asked about their experience of any side effects. Specifically, each woman allocated to UFH was assessed for compliance by being asked to show her injection sites and dispose of her syringes in our clinic. Each woman was given a placental pathology request form with a HEPRIN trial label attached, to direct the placenta to the Pathology Department after delivery. Gestational age, birth weight and any maternal complication (suspected abruption or preeclampsia) were recorded on the form at delivery. One woman delivered at a community hospital. Our Biobank attended the delivery of 17/31 (55%) women for immediate tissue sampling at Mount Sinai Hospital (for protein and molecular studies). Following maternal discharge from hospital, the outpatient chart, inpatient chart and electronic records were abstracted for complications and categorization of hypertensive complications was made using the ACOG guideline [23]. Information from the neonatal records was reviewed after discharge from hospital. All newborns requiring level III intensive care were admitted to the unit at Mount Sinai Hospital where the records were reviewed by a neonatologist (PS). Birth weight percentiles were assigned by sex and gestational age-specific Canadian data [24]. All women delivering at Mount Sinai Hospital had a 6–8-week postpartum visit and were then given a questionnaire to be completed at 4 months postpartum relating to their emotional wellbeing.

Study endpoints

The primary study outcome for this pilot feasibility trial was mean maternal anxiety during pregnancy as measured by the Spielberger State-Trait Inventory Self Evaluation Questionnaire [8,21] to evaluate whether women would be prepared to be randomized to multiple self-injections of heparin without increased anxiety. The short form Spielberger State-Trait Inventory Self Evaluation Questionnaire has been well utilized as a tool to evaluate maternal anxiety in both pregnancy and the postpartum period, and the outcome was chosen in recognition of the increased anxiety many women experience following the development of complications of pregnancy, in addition to the need for ongoing medical intervention. Specifically, we wanted to evaluate whether women would be prepared to be involved by randomization without increasing their anxiety through multiple self-injections of heparin. A mean score of < 15 is considered to be within the normal range [21].

Secondary outcomes included the following. (i) Adverse outcomes for the infant: intrauterine fetal death (defined as fetal death prior to birth and after trial entry); neonatal death (defined as death of a live born infant prior to hospital discharge, and excluding lethal congenital anomalies); infant birth weight less than the 10th centile for gestational age and infant sex; Apgar score < 7 at 5 min of age; and a composite neonatal morbidity rate between groups. Composite neonatal morbidity was defined by one or more of: a clinical diagnosis of respiratory distress syndrome (respiratory distress after birth with need for positive pressure ventilation or FiO2 requirement > 40% to maintain oxygenation in normal limits), intraventricular hemorrhage (IVH) grade III or IV on cranial ultrasound according to criteria suggested by Papile et al. [25], or stage 2 or 3 necrotizing enterocolitis defined according to Bell’s criteria [26]. (ii) Adverse outcomes for the woman: ultrasound diagnosis of IUGR (defined as absent or reversed end diastolic flow in the umbilical arteries and an estimated fetal weight < 10th percentile); preterm birth at < 32 weeks' gestation; vaginal bleeding, defined as antepartum hemorrhage after 20 weeks’ gestation if it was uncomplicated vaginal bleeding that settled spontaneously with hospitalized bed rest, and as abruption if vaginal bleeding was accompanied by an abnormal non-stress test requiring immediate Caesarean delivery and confirmed by the operator; and preeclampsia, eclampsia or HELLP syndrome, defined by current ACOG criteria [23]. Maternal emotional wellbeing was measured by a self-completed questionnaire during pregnancy, which related to anxiety and depression (as measured using the EPDS [22] and Short Form Speilberger State-Trait Inventory Self Evaluation Questionnaire [21]).

Placental pathology was performed by a dedicated perinatal pathologist according to standardized guidelines [27]. Placental weight percentile for gestational age (trimmed of cord, membranes and clot but before fixation in formaldehyde) was determined followed by gross description. Following a 48 h fixation, the placenta was serially-sectioned in 2-cm cuts. The percentage of abnormal tissue was estimated and grossly-visible lesions were removed for wax-embedding and paraffin histology, together with samples of normal placental parenchyma, umbilical cord and membranes.

Sample size

The outcome for this feasibility trial was mean anxiety score during pregnancy, as measured using the Short Form Speilberger State-Trait Inventory Self Evaluation questionnaire [21]. While a number of studies have described mean anxiety scores among women following identification of fetal anomalies [28–30], none were considered sufficiently comparable with our intended target population. A pragmatic approach was therefore used, in which a sample size of 32 women was calculated, with power to detect a difference of 1.0 standard deviation in mean anxiety score, with alpha 0.05 and power 80% (two-tailed test), a size comparable with the available literature.

Analysis

We analysed data on an intention to treat basis, blind to the allocated treatment. Dichotomous outcomes were compared with a chi-square test or Fisher’s exact test, with calculation of relative risks and 95% confidence intervals. We used Student’s t-test to compare normally distributed continuous data, and non-parametric tests (Wilcoxon rank sum) for skewed data. As baseline characteristics were sufficiently balanced at trial entry, no adjustments were required in the subsequent analyses.

Results

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

During the study period, 41 eligible women were approached, of whom 32 were randomized (16 women to the standard care group and 16 women to the UFH group). Reasons for not participating in the trial included women of non-English speaking background who were unable to give informed consent, an unwillingness to agree to a 50% risk of self-administration of heparin, or partner objection to the potential risk of heparin. No eligible patient declined randomization to seek heparin elsewhere and all eligible women continued care in our clinic. Women allocated to self-inject UFH did not complain of significant discomfort and none discontinued UFH prematurely. Self-injection was ascertained at each visit and could not be ascertained visually in only 1/16 women due to dark skin color. No woman allocated to standard care was found to have any bruises suggestive of heparin administration. Complete pregnancy and birth data were available for all 32/41 eligible women randomized as shown in Fig. 1. No newborn had aneuploidy or any major congenital abnormality.

image

Figure 1.  Consort flow diagram of women meeting trial entry criteria.

Download figure to PowerPoint

Baseline characteristics for the two treatment groups at the time of trial entry were comparable. The distribution of categories of abnormal placental function tests at trial entry was similar between the two treatment groups. However, within the category of abnormal maternal biochemistry, more women with elevated hCG or Inhibin were allocated to the UFH arm (Table 1). Seven women in the standard care group (43.8%) and six women in the UFH group (37.5%) had abnormalities in all three categories (maternal biochemistry, placental morphology and uterine artery Doppler), as shown in Table 2.

Table 1.   Maternal demographics at trial entry
 Standard care (n = 16)UFH (n = 16)
  1. Data are presented as n (%) or median (range), as appropriate. UFH, unfractionated heparin; BMI, body mass index; SGA, small-for-gestational age (birth weight < 10th percentile). *Note individual women in each arm may have had more than one or composite features listed defining a complex obstetric history.

Gestational age at randomization (weeks)22.1 (18.6–23.4)22.6 (18.1–23.9)
Maternal age (years)35 (25–42)33.5 (25–42)
Nulliparity4 (25)6 (37.5)
BMI (kg m−2)27.0 (20.4–41.7)28.3 (20.0–45.5)
BMI ≥ 304 (25)8 (50)
Smokers01 (6.3)
Ethnicity
 Caucasian8 (50)6 (38)
 Asian7 (44)6 (38)
 African1 (6)4 (25)
Previous complex obstetric history*8 (50)6 (37.5)
 Stillbirth (> 20 weeks)4 (25)4 (25)
 Preterm delivery (< 32 weeks)2 (12.5)3 (18.8)
 ≥ 2 pregnancy losses < 20 weeks1 (6.3)1 (6.3)
 Previous placental abruption01 (3.1)
 Previous preeclampsia2 (12.5)1 (6.3)
 Previous SGA infant6 (37.5)1 (6.3)
Complex medical history2 (12.5)0
 Chronic renal disease1 (6.3)0
 Chronic hypertension2 (12.5)0
Table 2.   Distribution of abnormal placental function tests at randomization
 Standard care (n = 16)UFH (n = 16)
  1. Data are presented as n (%).Women may have more than one abnormality in each category. *n = 14 tested in standard care, 15 tested in UFH, n = 15 tested in standard care, 14 tested in UFH, n = 7 tested in standard care, 5 tested in heparin, §n = 13 for each group. UFH, unfractionated heparin; ECLs, echogenic cystic lesions; PAPP-A, pregnancy associated plasma protein-A; AFP, alpha-fetoprotein; hCG, human chorionic gonadotropin.

Abnormal maternal biochemistry13 (81.3)15 (93.8)
 PAPP-A < 0.35 MoM*8 (57.1)8 (53.3)
 AFP > 2.0 MoM9 (60)10 (71.4)
 Inhibin > 3.0 MoM1 (14.3)4 (80)
 Total hCG > 4.0 MoM§1 (7.7)8 (61.5)
Abnormal placental morphology14 (87.5)11 (68.8)
 Thickness > 4 cm or  >50% maximum length6 (37.5)4 (25)
 Maximum length < 10 cm9 (56.3)6 (37.5)
 Heterogenous texture/ECLs7 (43.8)4 (25)
Abnormal uterine artery Doppler12 (75)12 (75)
All three categories abnormal7 (43.8)6 (37.5)

Maternal health outcomes

There were no statistically significant differences identified between the two treatment groups in the mean anxiety score, or in the number of women with an EPDS score ≥ 12 (Table 3). There were no statistically significant differences identified between the two treatment groups in the occurrence of all preeclampsia, or severe preeclampsia ± HELLP syndrome. Only four women (12.5%) had healthy term pregnancies (delivery > 37 weeks without evidence of preeclampsia or IUGR). In five women (15.6%), the lowest platelet count before delivery was < 120 × 10−9 L−1. This was asymptomatic in four women, while one woman developed an abruption. She was admitted with mild vaginal bleeding and some uterine activity. She received Celestone for fetal lung maturation. Two days later, an abruption was clinically evident and she required Caeserean delivery under general anesthesia. A significant abruption was confirmed.

Table 3.   Maternal outcomes
VariableStandard care (n = 16)UFH (n = 16)RR (95% CI)P value
  1. Data are presented as n (%) or mean (SD), or as relative risk (RR) with 95% confidence interval, as appropriate. EPDS, Edinburgh Postnatal Depression Score; HELLP, hemolysis, elevated liver enzymes and a low platelet count.

Mean anxiety score14.2 ± 1.614.0 ± 1.8 0.574
EPDS ≥ 121 (6.3)2 (12.6)1.66 (0.16–17.100.641
Caesarean delivery8 (16)9 (56.3) 1.000
Severe preeclampsia2 (12.5)6 (37.5)0.33 (0.08–1.41)0.220
HELLP01 (6.3)0.33 (0.01–7.621.000
Placental abruption01 (6.3)0.33 (0.01–7.62)1.000

Delivery and infant health outcomes

No statistically significant differences were identified between the two treatment groups in gestational age at birth, Apgar score of < 7 at 5 min of age, infant birth weight < 3rd centile, perinatal mortality, neonatal intensive care unit admission, or composite neonatal morbidity (Table 4).

Table 4.   Neonatal outcomes
VariableStandard care (n = 16)UFH (n = 16)RR (95% CI)P value
  1. Data are presented as n (%) or median (range), or as relative risk (RR) with 95% confidence interval, as appropriate. UFH, unfractionated heparin; SGA, small-for-gestational-age (birth weight < 10th centile); IUGR, intrauterine growth restriction (birth weight < 10th centile with either absent or reversed end diastolic flow, or delivery < 32 weeks); NICU, neonatal intensive care unit; SB, stillborn; NND, neonatal death. *Denominator for standard care is 15 because one infant was stillborn.

Mean gestational age at birth (weeks)35.6 (28.4–38.3)34.3 (27.9–38.4) 0.481
Preterm birth at < 32 weeks gestation5 (31.3)5 (31.3)1.00 (0.36–2.79)1.000
Male9 (56)9 (56) 1.000
Median birth weight (g)1795 (470–3295)1860 (730–3050) 0.759
Birth weight < 10th centile (SGA)12 (75)6 (37.5)2.00 (1.00–4.00)0.073
Birth weight < 3rd centile5 (31.3)4 (25)1.25 (0.41–3.82)1.000
IUGR4 (25)1 (6.3)4.00 (0.50–31.98)0.333
Apgars (min)
 18 (0–9)8 (1–9) 0.928
 59 (0–9)9 (6–9) 0.585
NICU admission*7 (46.7)10 (62.5)0.70 (0.36–1.37)0.479
Perinatal mortality3 (18.8)07.00 (0.39–125.44)0.226
Composite neonatal morbidity*3 (20)3 (18.8)1.00 (0.24–4.23)1.000

Placental pathology

A total of 31/32 placentas were submitted for pathological examination by a dedicated perinatal pathologist (SK) who was blinded to treatment allocation. Only five placentas were normal at delivery (weight > 10th percentile for gestation with no gross lesions; UFH group n = 4; standard care group n = 1). No statistically significant differences were found between the two groups for gross pathology or vascular lesions (infarction, intervillous thrombosis and hemorrhage) (Table 5).

Table 5.   Placental pathology
VariableStandard care* (n = 15)UFH (n = 16)P value
  1. Data are presented as n (%) or mean, as appropriate. UFH, unfractionated heparin. *One placenta was not sampled in the standard care group. n = 14 standard care, 15 UFH.

Gross pathology
 Placental weight < 10th centile7 (46.7)4 (25)1.000
 Accessory lobe1 (6.7)1 (6.3)1.000
 Two vessel cord3 (20)00.101
 Velamentous umbilical cord insertion3 (21.4)1 (6.7)0.330
Histopathology
 Infarction4 (26.7)3 (18.8)0.685
 Intervillous thrombosis7 (46.7)2 (13.3)0.109
 Large retroplacental or subchorionic hemorrhage5 (33.3)1 (6.3)0.083

Discussion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

The increasing use of prophylactic doses of heparin in the belief that it will improve a range of pregnancy outcomes attributable to placental dysfunction is concerning for several reasons, including cost, side effects, and provision of safe regional anesthesia at delivery. The range of inadequately powered randomized controlled trials suggesting clinical benefit encompasses implantation at in vitro fertilization [10], and perinatal outcomes in both thrombophilia screen positive [2] and negative [5,31,32] women with prior adverse outcomes. Conversely, two recent trials found no benefit of heparin in preventing recurrent miscarriages in either the presence or absence of thrombophilia [31,33]. The rationale of such studies is based on the assumption that heparin prevents placental damage via an anticoagulant effect, though none of these studies assessed the target organ by performing placental pathology at delivery. Furthermore, the low rate of serious adverse perinatal outcomes in these trials suggests that a majority of participants probably had adequate placental function to sustain their near term pregnancies.

Recognizing the need to develop a cost-effective strategy to address the role of heparin in this context, we performed a pilot randomized controlled trial in women with a prenatal diagnosis of placental insufficiency in the second trimester. The inclusion criteria were based on our previously validated model for identifying women with positive predictive values for adverse perinatal outcomes attributable to placental dysfunction up to 50% [12] and a high likelihood of ischemic-thrombotic placental pathology [16]. We excluded a minority of otherwise eligible women due to participation in an ongoing multicenter trial in thrombophilia screen-positive women (http://clinicaltrials.gov/ct2/show/NCT00967382) and chose a higher (7500 IU/BD) dose of the low-cost unfractionated type of heparin to explore efficacy. We achieved a high rate of enrollment with no postrandomization cross-over in either direction. We were able to analyse 31/32 placentas after delivery. As expected in this pilot trial sample size, we found no statistically significant differences in the prespecified maternal and infant health outcomes. Importantly, there were no differences identified in maternal anxiety or risk of depression during pregnancy.

The presence of maternal anxiety has been well recognized among healthy pregnant women and demonstrated to be associated with negative expectations about motherhood [34], poorer adjustment to motherhood [35] and postpartum mood disorders, particularly postpartum depression [36,37]. Furthermore, there is a well-described literature identifying that women experience increased anxiety if they have pregnancy complications, including miscarriage [38], fetal aneuploidy [39] and need for invasive prenatal testing [40,41] or investigation [28], in addition to medical complications, including gestational diabetes [42]. The use of the six-item short form Spielberger State-Trait Inventory Self Evaluation Questionnaire [21] has been well reported and validated as a reliable assessment of anxiety during pregnancy. Importantly, our pilot randomized trial did not identify any increase in maternal anxiety score or risk of depression in this high-risk antenatal population, attributable to regular self-administration of subcutaneous injections.

The strengths of this pilot trial are that it utilized high quality randomized trial methodology, and provided valuable information regarding the feasibility of any further definitive studies. Our findings are consistent with those presented in the Cochrane Systematic Review evaluating the role of antithrombotic therapy for women at risk of placental dysfunction [3]. When our data and that of Gris et al. [32] are incorporated into the meta-analysis for the outcome of perinatal mortality, there is no statistically significant difference identified between the use of heparin therapy and no treatment, although the combined available sample size is underpowered (five studies, 429 participants; 6/228 heparin therapy vs. 17/201 no treatment; risk ratio 0.42; 95% CI 0.18–1.01). Utilizing the information available from this updated meta-analysis, a definitive trial with sample size of approximately 1200 women would be required to detect a 50% reduction in the risk of perinatal death from 8.46% to 4.23% (alpha 0.05; power 80%). A similar sized trial would be able to detect a more modest reduction of 30% in a composite outcome of perinatal death or serious infant morbidity from 25% to 17.5% (alpha 0.05; power 90%), as suggested by this pilot study.

A novel aspect of our trial design is the adoption of a strategy to identify elements of placental dysfunction using a combination of reinterpretation of maternal serum screening test data, placental morphology and uterine artery Doppler [12]. An extensive interest in the concept of multi-parameter screening for placental dysfunction to date has been limited by focusing on just one element of adverse outcome, for example preeclampsia [43], and the fact that the blood tests used in risk modelling are performed in a batched retrospective manner and are thus not available for real-time clinical decision-making [44]. We operated a real-time strategy by the integration of maternal serum screening data [13] with ultrasound imaging [12,16]. While maternal serum screening test abnormalities do not achieve sufficient precision to report risks of adverse perinatal outcomes in the care of low-risk women [13], when used in combination with two additional ultrasound tests (placental morphology and uterine artery Doppler) a subset of women with up to 50% positive predictive value for perinatal death and delivery before 34 weeks' gestation can be identified [12]. Our current study validates this logic in a prospective manner because six infants, including all three perinatal deaths, were born before 32 weeks while only four women had healthy term pregnancies (delivery > 37 weeks with no evidence of IUGR or preeclampsia). By comparison, one perinatal death at 24 weeks amongst 110 women randomized to low-molecular-weight heparin was found in a similar trial based on clinical risk factors alone [5].

Our study is the first randomized controlled trial to report the effects of heparin on its target organ. The assumption in previous trials, that infarction is the dominant pathology mediating perinatal death and adverse outcomes, may be flawed because the majority of infarcted placentas exhibit other significant pathologies that limit placental function. These elements are being small for gestational age, with abnormal placental villous structure and non-infectious inflammatory lesions [8]. We found one-third of the placentas were small for gestational age, consistent with previous data showing a 7-fold increased risk of a small placenta in clinically high-risk women with abnormal uterine artery Doppler [16]. Placental infarction was detected in only 7/31 (22.5%) placentas, while lesions attributable to accidental hemorrhage (intervillous thrombosis, large retroplacental or subchorionic hemorrhage) were collectively more common and found mostly in the control arm. This observation is both surprising and reassuring because investigators are frequently concerned that heparin anticoagulation may increase the risk of hemorrhagic complications in pregnancy, especially abruption. Prenatal screening of placental function may aid future trials of heparin by defining the type of underlying placental insufficiency so as to focus on those at most risk of infarction. As an example, the subset of women with low PAPP-A and small abnormal placentas [15] are destined to develop severe IUGR rather than preeclampsia, due to defective formation of a gas and nutrient-exchanging placenta; such pregnancies may not respond to the anticoagulant action of heparin [45,46].

Two potential limitations of our study design deserve discussion. First, we chose UFH rather than LMWH. This decision was made on cost within the grant budget, to avoid pharmaceutical support. Both related trials that were larger [2,5,32] used LMWH and were not conducted independently of the drug manufacturer. Heparins have complex cellular actions that include regulating angiogenesis [11]. UFH and LMWH differ in their in vitro angiogenic responses and in their survival properties for metastatic cancer patients [47]. We recently found that LMWH interacts with first trimester placental villi to exert a stronger proangiogenic response than UFH in vitro [48]. As UFH may be less potent than LMWH, we therefore chose a higher dose (7500 IU BD) to ensure efficacy as a prophylactic drug. Our observation of a higher rate of severe preeclampsia in the UFH arm of this pilot trial is surprising because UFH is predicted, from our in vitro data, to exert a partial proangiogenic response when it interacts with placental villi. Recently, Sela et al. [49] demonstrated that heparin promotes release of bound sFlt1 from the human placenta to increase circulating sFlt1 levels two-fold. As circulating maternal sFlt1 levels rise several weeks prior to the development of severe preeclampsia [50], we speculate that the higher rate of severe preeclampsia observed in our pilot study could be due to the selection of women with a high rate of preclinical placental dysfunction, in whom UFH may further elevate sFlt1 to exacerbate disease risk. An alternative explanation may relate to sample size because an excess of women allocated to the UFH arm had an abnormal biochemical test result due to elevated hCG or inhibin, which we more recently have recognized to be associated with severe preeclampsia from placental pathology [51]. Given the small sample size, we accept that no specific conclusion can be drawn on the maternal benefits or risks of heparin, other than to underscore that our trial design, by virtue of its high negative predictive value [12], substantially reduces the proportion of women exposed to heparin in a trial context. In future studies, we suggest that serial determination of maternal circulating pro- and anti-angiogenic growth factors followed by detailed placental analysis will effectively test the hypothesis that heparin exerts negative effects upon high-risk pregnancies with placental dysfunction via augmented release of sFlt1. Given that LMWH exerts stronger proangiogenic effects in vitro [48] we accept that it will be important to use LMWH in future adequately-powered trials of this design to exploit this proangiogenic action of heparin in pregnancy.

A second potential limitation of our study was the ongoing use of low-dose aspirin in the standard care arm. For safety reasons, our trial design precluded the ongoing use of low-dose aspirin in the UFH treatment arm while a decision to take low-dose aspirin was allowed in the standard care arm to facilitate recruitment. A recent systematic review of the role of low-dose aspirin in the prevention of preeclampsia and/or IUGR in women with abnormal uterine artery Doppler ultrasound demonstrated that a reduction in preeclampsia was confined to women who started the drug in early pregnancy [52]. An equal subset of women randomized to UFH, who therefore discontinued aspirin, had at least been exposed to aspirin from the first trimester until randomization. Given the low efficacy of aspirin in preventing preeclampsia following second trimester randomization [53], together with the placental pathology findings, demonstrating that placental infarction was not the dominant pathology, we believe that this difference in aspirin utilization does not undermine our general conclusions. Finally, the low rate of placental infarction in both arms is a valid counter-argument against the criticism that this trial design commenced heparin too late, or that it differed in the proportion of women who continued to take aspirin.

Given the cost and potential side effects of heparin during pregnancy, we believe the deployment of a strategy of ‘placental function screening’ to reduce trial entry to women with a high positive predictive value of extreme preterm delivery in association with placental developmental and vascular pathology, is an appropriate clinical strategy. This is based on a previously-validated screening program in a clinically high-risk cohort, where the positive predictive value for significant adverse perinatal outcomes was up to 50% [12]. The high rate of serious outcomes in this pilot trial was further validated by placental pathologic analysis. Our research ethics board approval did not include consent to capture data for either screen negative women or eligible women who did not consent to randomization. We therefore estimated the number of screened women based on our prior cohort data [12] and thus could not derive the false-negative rate of adverse perinatal outcomes, and the overall effectiveness of this study design. Nevertheless our study design and findings, including placental pathology data, challenge the widely-prevailing view that pregnant women should receive prophylactic heparin to improve perinatal outcomes based solely on clinical risk factors for placental insufficiency.

Addendum

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

J. Kingdom: Obtained funding, conducted trial, wrote manuscript. M. Walker: Data management/analysis, manuscript writing/editing. L. Proctor: Manuscript editing. S. Keating: Placental pathology analysis. P. Shah: Perinatal and newborn outcome data analysis, manuscript editing. A. McLeod: Review of hematologic issues for trial patients, provision and care of heparin pts. J. Keunen: Manuscript review/editing. R. Windrim: Manuscript review/editing. J. Dodd: Major role in obtaining grant funding, data supervision, edited manuscript.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

Physician’s Services Inc. Grant #07-04 to J. Keunen and J.M. Dodd; Rose Torno Chair grant, Mount Sinai Hospital, to J.C.P. Kingdom; NHMRC Practitioner Fellowship ID 627005 to J.M. Dodd; and a grant from the Breslin family Foundation, Toronto.

Disclosure of Conflict of Interests

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References

The authors state that they have no conflict of interest.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Addendum
  8. Acknowledgements
  9. Disclosure of Conflict of Interests
  10. References
  • 1
    Buyse FG, Wormgoor BH, Bernard JT, Koudstaal J. Anticoagulant therapy of patients with repeated placental infarction. Obstet Gynecol 1974; 43: 8448.
  • 2
    Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Mares P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 36959.
  • 3
    Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010; 6: CD006780.
  • 4
    Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 8691.
  • 5
    Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 5864.
  • 6
    Kincaid-Smith P, North RA, Fairley KF, Kloss M, Ihle BU. Prevention of pre-eclampsia in high risk women with renal disease: a prospective randomized trial of heparin and dipyridamole. Nephrology 1995; 1: 297300.
  • 7
    Yu YH, Shen LY, Zhong M, Zhang Y, Su GD, Gao YF, Quan S, Zeng L. [Effect of heparin on fetal growth restriction]. Zhonghua Fu Chan Ke Za Zhi 2004; 39: 7936.
  • 8
    Franco C, Walker M, Robertson J, Fitzgerald B, Keating S, McLeod A, Kingdom JC. Placental infarction and thrombophilia. Obstet Gynecol 2011; 117: 92934.
  • 9
    Sarig G, Vidergor G, Brenner B. Assessment and management of high-risk pregnancies in women with thrombophilia. Blood Rev 2009; 23: 1437.
  • 10
    Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, Balaban B. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod 2009; 24: 16407.
  • 11
    Drewlo S, Walker M, McLeod A, Dodd J, Kingdom JC. Heparin in human placental development and the prevention of placental complications of pregnancy. Fetal Matern Med Rev 2010; 21: 119.
  • 12
    Toal M, Chan C, Fallah S, Alkazaleh F, Chaddha V, Windrim RC, Kingdom JC. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007; 196: 363 e17.
  • 13
    Dugoff L. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010; 115: 105261.
  • 14
    Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, Zwinderman AH, Robson SC, Bindels PJ, Kleijnen J, Khan KS. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 70111.
  • 15
    Proctor LK, Toal M, Keating S, Chitayat D, Okun N, Windrim RC, Smith GC, Kingdom JC. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2009; 34: 27482.
  • 16
    Toal M, Keating S, Machin G, Dodd J, Adamson SL, Windrim RC, Kingdom JC. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol 2008; 198: 330 e17.
  • 17
    Proctor LK, Whittle WL, Keating S, Viero S, Kingdom JC. Pathologic basis of echogenic cystic lesions in the human placenta: role of ultrasound-guided wire localization. Placenta 2010; 31: 11115.
  • 18
    Jauniaux E, Moscoso G, Campbell S, Gibb D, Driver M, Nicolaides KH. Correlation of ultrasound and pathologic findings of placental anomalies in pregnancies with elevated maternal serum alpha-fetoprotein. Eur J Obstet Gynecol Reprod Biol 1990; 37: 21930.
  • 19
    Bower S, Bewley S, Campbell S. Improved prediction of preeclampsia by two-stage screening of uterine arteries using the early diastolic notch and color Doppler imaging. Obstet Gynecol 1993; 82: 7883.
  • 20
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 21
    Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31 (Pt 3): 3016.
    Direct Link:
  • 22
    Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150: 7826.
  • 23
    ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 15967.
  • 24
    Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Breart G. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108: E35.
  • 25
    Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 52934.
  • 26
    Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187: 17.
  • 27
    Kraus FT, Redline RW, Gersell DJ, Nelson DM, Dicke JM. AFIP Atlas of Nontumour Pathology: Placental Pathology. Washington, DC: American Registry of Pathology, 2004.
  • 28
    Rosenberg KB, Monk C, Glickstein JS, Levasseur SM, Simpson LL, Kleinman CS, Williams IA. Referral for fetal echocardiography is associated with increased maternal anxiety. J Psychosom Obstet Gynaecol 2010; 31: 609.
  • 29
    Larsson AK, Svalenius EC, Marsal K, Dykes AK. Parental level of anxiety, sense of coherence and state of mind when choroid plexus cysts have been identified at a routine ultrasound examination in the second trimester of pregnancy: a case control study. J Psychosom Obstet Gynaecol 2009; 30: 95100.
  • 30
    Aite L, Zaccara A, Trucchi A, Brizzi C, Nahom A, Iacobelli B, Capolupo I, Bagolan P. When uncertainty generates more anxiety than severity: the prenatal experience with cystic adenomatoid malformation of the lung. J Perinat Med 2009; 37: 53942.
  • 31
    Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Buller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 158696.
  • 32
    Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 7719.
  • 33
    Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 27987.
  • 34
    Hart R, McMahon CA. Mood state and psychological adjustment to pregnancy. Arch Womens Ment Health 2006; 9: 32937.
  • 35
    Barnett B, Schaafsma MF, Guzman AM, Parker GB. Maternal anxiety: a 5-year review of an intervention study. J Child Psychol Psychiatry 1991; 32: 42338.
  • 36
    Austin MP, Tully L, Parker G. Examining the relationship between antenatal anxiety and postnatal depression. J Affect Disord 2007; 101: 16974.
  • 37
    Grant KA, McMahon C, Austin MP. Maternal anxiety during the transition to parenthood: a prospective study. J Affect Disord 2008; 108: 10111.
  • 38
    Fertl KI, Bergner A, Beyer R, Klapp BF, Rauchfuss M. Levels and effects of different forms of anxiety during pregnancy after a prior miscarriage. Eur J Obstet Gynecol Reprod Biol 2009; 142: 239.
  • 39
    Lee MJ, Roman AS, Lusskin S, Chen D, Dulay A, Funai EF, Monteagudo A. Maternal anxiety and ultrasound markers for aneuploidy in a multiethnic population. Prenat Diagn 2007; 27: 405.
  • 40
    Cheng PJ, Wu TL, Shaw SW, Chueh HY, Lin CT, Hsu JJ, Hsieh TT, Soong YK. Anxiety levels in women undergoing prenatal maternal serum screening for Down syndrome: the effect of a fast reporting system by mobile phone short-message service. Prenat Diagn 2008; 28: 41721.
  • 41
    Hewison J, Nixon J, Fountain J, Hawkins K, Jones CR, Mason G, Morley S, Thornton JG. A randomised trial of two methods of issuing prenatal test results: the ARIA (Amniocentesis Results: Investigation of Anxiety) trial. BJOG 2007; 114: 4628.
  • 42
    Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 247786.
  • 43
    Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 6674.
  • 44
    Thilaganathan B, Wormald B, Zanardini C, Sheldon J, Ralph E, Papageorghiou AT. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 12338.
  • 45
    Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JC. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol 1996; 175: 153442.
  • 46
    Nordenvall M, Ullberg U, Laurin J, Lingman G, Sandstedt B, Ulmsten U. Placental morphology in relation to umbilical artery blood velocity waveforms. Eur J Obstet Gynecol Reprod Biol 1991; 40: 17990.
  • 47
    Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476.
  • 48
    Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol 2011; 117: 137583.
  • 49
    Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108: 106370.
  • 50
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 9921005.
  • 51
    Fitzgerald B, Levytska K, Kingdom J, Walker M, Baczyk D, Keating S. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta 2011; 32: 33945.
  • 52
    Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 2009; 31: 81826.
  • 53
    Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003; 22: 2339.